BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11927223)

  • 21. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
    Ormrod D; Scott LJ; Perry CM
    Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study.
    Leruez-Ville M; Ghout I; Bussières L; Stirnemann J; Magny JF; Couderc S; Salomon LJ; Guilleminot T; Aegerter P; Benoist G; Winer N; Picone O; Jacquemard F; Ville Y
    Am J Obstet Gynecol; 2016 Oct; 215(4):462.e1-462.e10. PubMed ID: 27083761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lowering immunosuppression is safe and effective to treat altered pattern of CMV infection in renal transplant recipients on valaciclovir prophylaxis.
    Anglicheau D; Lautrette A; Scieux C; Thervet E; Martinez F; Flamant M; Morinet F; Legendre C
    Transplant Proc; 2002 Nov; 34(7):2826-7. PubMed ID: 12431624
    [No Abstract]   [Full Text] [Related]  

  • 25. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.
    Reischig T; Kacer M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):771-9. PubMed ID: 25252996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
    Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation.
    Legendre CM; Norman DJ; Keating MR; Maclaine GD; Grant DM
    Transplantation; 2000 Nov; 70(10):1463-8. PubMed ID: 11118091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir.
    Sund F; Wahlberg J; Eriksson BM
    J Clin Virol; 2001 Dec; 23(1-2):107-11. PubMed ID: 11595589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of lowering immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study.
    Anglicheau D; Lautrette A; Scieux C; Flamant M; Morinet F; Legendre C
    Nephrol Dial Transplant; 2003 Aug; 18(8):1654-6. PubMed ID: 12897109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maternal valacyclovir and infant cytomegalovirus acquisition: a randomized controlled trial among HIV-infected women.
    Roxby AC; Atkinson C; Asbjörnsdóttir K; Farquhar C; Kiarie JN; Drake AL; Wald A; Boeckh M; Richardson B; Emery V; John-Stewart G; Slyker JA
    PLoS One; 2014; 9(2):e87855. PubMed ID: 24504006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
    Jongsma H; Bouts AH; Cornelissen EA; Beersma MF; Cransberg K
    Pediatr Transplant; 2013 Sep; 17(6):510-7. PubMed ID: 23890076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytomegalovirus prophylaxis in solid organ transplantation.
    Alexopoulos SP; Lindberg L; Subramanyan RK; Matsuoka L
    Curr Med Chem; 2012; 19(35):5957-63. PubMed ID: 22963558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy.
    Ko EJ; Yu JH; Yang CW; Chung BH
    Korean J Intern Med; 2019 Mar; 34(2):375-382. PubMed ID: 29237252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
    Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
    Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-Dose Valacyclovir for Cytomegalovirus Infection Prophylaxis After a Heart Transplant.
    Kervan U; Kucuker SA; Kocabeyoglu SS; Unal EU; Ozatik MA; Sert DE; Kavasoglu K; Tezer AY; Pac M
    Exp Clin Transplant; 2016 Oct; 14(5):551-554. PubMed ID: 26976362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful use of oral valacyclovir in post-transplant cytomegalovirus infection in renal allograft recipients.
    Himmelmann-Jud B; Wüthrich RP; Weinreich T; Binswanger U
    Nephrol Dial Transplant; 1998 May; 13(5):1326-7. PubMed ID: 9623588
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.
    Falagas ME; Vardakas KZ
    Clin Microbiol Infect; 2006 Jul; 12(7):603-5. PubMed ID: 16774555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial.
    Chanouzas D; Dyall L; Nightingale P; Ferro C; Moss P; Morgan MD; Harper L
    Trials; 2016 Jul; 17(1):338. PubMed ID: 27450392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.